ProMIS to Present Two Vaccine Posters Targeting ALS, Parkinson’s at AD/PD 2026
ProMIS Neurosciences will present two scientific posters on March 20, 2026 at AD/PD™ 2026 in Copenhagen, detailing vaccine designs targeting misfolded TDP-43 in ALS and alpha-synuclein in Parkinson’s based on its proprietary EpiSelect™ platform. These data underscore progress in its ALS and Parkinson’s pipeline candidates.
1. AD/PD™ 2026 Poster Presentations
ProMIS Neurosciences will present two posters at the Alzheimer’s & Parkinson’s Diseases Conference in Copenhagen on March 20, 2026, including an oral symposium on TDP-43 vaccine design and a symposium on alpha-synuclein vaccination responses.
2. Vaccine Designs for Misfolded Proteins
Poster #1 details the rational design of a TDP-43 vaccine targeting pathogenic epitopes implicated in ALS and frontotemporal dementia, while Poster #2 describes vaccination with conformational epitopes computationally modeled to elicit antibodies selective for toxic alpha-synuclein species in Parkinson’s disease.
3. EpiSelect™ Platform and Pipeline Advancement
The data leverage ProMIS’s proprietary EpiSelect™ discovery engine to identify disease-specific conformational epitopes, underscoring advancement of its ALS and Parkinson’s pipeline candidates toward preclinical and clinical evaluation.